• Company
• Imfinzi combo drug Imjudo can be prescribed at hospitals
• by Eo, Yun-Ho Nov 13, 2024 05:54am

• Company
• Treatment-refractory Dravet syndrome calls for new options
• by Whang, byung-woo Nov 13, 2024 05:54am

• Company
• 'Choline alfoscerate' prescription market continues to grow
• by Chon, Seung-Hyun Nov 13, 2024 05:54am

• Company
• Asthma drug 'Monterizine' sales rise despite generic entries
• by Kim, Jin-Gu Nov 12, 2024 05:51am

• Company
• 'Vabysmo' for macular deg associated RVO indication expected
• by Eo, Yun-Ho Nov 12, 2024 05:51am

• CG Invites' personalized cancer vaccine shows promise
• by 강은희 Nov 12, 2024 05:51am

• Opinion
• [Reporter's View] Patience is required to foster K-Bios
• by Whang, byung-woo Nov 12, 2024 05:51am

• Company
• Generic companies seek early entry into KRW 100 bil Tagrisso
• by Kim, Jin-Gu Nov 12, 2024 05:51am

• Policy
• NHIS-Roche enters pricing negotiations for Perjeta’s reimb
• by Lee, Tak-Sun Nov 12, 2024 05:50am

• Company
• Will Lorviqua be reimbursed as a first-line therapy in KOR?
• by Eo, Yun-Ho Nov 11, 2024 05:49am